Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAS 41004 formulations versus placebo and Daivobet in a psoriasis plaque test
2010-022281-27Phase 2Completed
- Sponsor
- Almirall
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of LAS41004 IMP5 and calcipotriol + betamethasone in plaque psoriasis (5 arms), sponsored by Almirall. Primary endpoint: AUC of width of the echo-lucent band at the dermo-epidermal junction. Started Sep 2010; status: completed.
02
Drugs
LAS41004 IMP5calcipotriol + betamethasone
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2010-022281-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022281-27.